Study guide

14.2 Osteoarthritis, Rheumatoid Arthritis & Gout

PEBC Pharmacist Qualifying Examination Part I MCQ

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Canadian Pharmacy Regulatory Framework & Federal Legislation

1.1 Food and Drugs Act, Regulations, and Health Canada Oversight 1.2 Controlled Drugs and Substances Act (CDSA) & Controlled Substances Regulations (CSR) 1.3 NAPRA Drug Scheduling Framework & National Model Standards of Practice

2 Chapter 2: Ethics, Scope of Practice & Safety Culture

2.1 Professional Ethics, Fiduciary Duty & Health Information Privacy 2.2 Expanded Scope of Practice: Minor Ailments Prescribing, Renewals & Injections 2.3 Equity, Diversity, Inclusion, Cultural Safety & Continuous Quality Improvement

3 Chapter 3: Pharmaceutical Calculations & Posology

3.1 Concentrations, Dilutions, Alligations & Reconstitution 3.2 Dosing by Weight/BSA, Days Supply & Pediatric/Geriatric Dose Adjustments 3.3 IV Infusion Rates, Drop Factors, Osmolarity & Creatinine Clearance (Cockcroft-Gault)

4 Chapter 4: Compounding, Dispensing & Product Integrity

4.1 Non-Sterile Compounding & Beyond-Use Dating (NAPRA Standards) 4.2 Sterile Preparations & Hazardous Drug Handling (NAPRA / NIOSH Principles) 4.3 Prescription Verification, Auxiliary Labeling, Cold Chain & Medication Incident Prevention (ISMP Canada) 4.4 Dispensing Operations: Interchangeability, Adjudication, Compliance Packaging, Release & Inventory Control

5 Chapter 5: Clinical Pharmacology & Pharmacokinetics

5.1 Pharmacokinetic Principles: Clearance, Volume of Distribution, Half-life & Steady State 5.2 Cytochrome P450 Enzymes, Transporters & Significant Drug-Drug Interactions 5.3 Therapeutic Drug Monitoring (TDM), Narrow Therapeutic Index Drugs & Toxicities

6 Chapter 6: Evidence-Based Medicine & Literature Appraisal

6.1 Study Designs, Bias & Levels of Evidence in Clinical Research 6.2 Biostatistics: ARR, RRR, NNT, NNH, Confidence Intervals & P-values 6.3 Applying Canadian Practice Guidelines to Clinical Decision-Making 6.4 Drug Information Practice, Diagnostic Test Accuracy & Pharmacoeconomics

7 Chapter 7: Cardiovascular Pharmacotherapy: Hypertension, Dyslipidemia & CAD

7.1 Hypertension Management (Hypertension Canada Guidelines, Targets & Regimens) 7.2 Dyslipidemia & Atherosclerotic Cardiovascular Disease (CCS Guidelines & Statin Therapy) 7.3 Ischemic Heart Disease & Acute Coronary Syndromes (Antiplatelet & Antianginal Therapy)

8 Chapter 8: Cardiovascular Pharmacotherapy: Heart Failure, Arrhythmias & Anticoagulation

8.1 Heart Failure with Reduced & Preserved Ejection Fraction (GDMT & Monitoring) 8.2 Atrial Fibrillation, Arrhythmias & Rate vs. Rhythm Control 8.3 Venous Thromboembolism & Anticoagulation Therapy (DOACs, Warfarin & Thrombosis Canada)

9 Chapter 9: Endocrine & Metabolic Disorders

9.1 Type 2 Diabetes: Glycemic Targets, Non-Insulin Pharmacotherapy (Diabetes Canada) 9.2 Insulin Regimens, Type 1 Diabetes, Hypoglycemia & Diabetic Emergencies (DKA/HHS) 9.3 Thyroid Disorders & Osteoporosis (Diagnostic Parameters & Therapeutic Management)

10 Chapter 10: Respiratory & Gastrointestinal Disorders

10.1 Asthma Management & Exacerbations (CTS Guidelines, Relievers & Controllers) 10.2 Chronic Obstructive Pulmonary Disease (COPD) & Inhaler Delivery Systems 10.3 Gastroesophageal Reflux Disease (GERD), Peptic Ulcer Disease & GI Bleeding 10.4 Lower GI & Liver Disorders: Constipation, Diarrhea, IBS, IBD & Cirrhosis

11 Chapter 11: Infectious Diseases & Antimicrobial Stewardship

11.1 Respiratory Tract Infections: Otitis, Sinusitis, Pharyngitis, CAP & HAP 11.2 Urinary Tract, Skin/Soft Tissue & Sexually Transmitted Infections 11.3 Systemic Infections, Clostridioides difficile & Antimicrobial Stewardship Principles 11.4 HIV Prevention & Treatment, Viral Hepatitis, Tuberculosis & Fungal Infections

12 Chapter 12: Central Nervous System & Mental Health

12.1 Major Depressive Disorder & Anxiety Disorders (First-Line Agents & Safety) 12.2 Bipolar Disorder, Schizophrenia & Psychopharmacology Monitoring 12.3 Epilepsy, Seizure Types, Antiseizure Medications & Neuropathic Pain 12.4 Dementia, Parkinson Disease, Migraine, Insomnia & Restless Legs Syndrome

13 Chapter 13: Special Populations, Pain Management & Substance Use

13.1 Acute & Chronic Pain Management: Multimodal Analgesia & Opioid Stewardship 13.2 Substance Use Disorders: Opioid Agonist Therapy, Harm Reduction & Alcohol Withdrawal 13.3 Special Populations: Pharmacotherapy in Pregnancy, Lactation & Geriatrics (Deprescribing / Beers) 13.4 Palliative Care & Pediatric Pharmacotherapy

14 Chapter 14: Renal, Rheumatologic, Hematologic & Oncology Supportive Care

14.1 Chronic Kidney Disease, Acute Kidney Injury & Electrolyte Disorders 14.2 Osteoarthritis, Rheumatoid Arthritis & Gout 14.3 Anemias & Oncology Supportive Care

15 Chapter 15: Minor Ailments, Dermatology and Women's & Men's Health

15.1 Minor Ailments I: Allergic Rhinitis, Colds & Influenza, Eye and Ear Conditions 15.2 Minor Ailments II: Acne, Dermatitis, Psoriasis, Lice, Scabies & Sun Protection 15.3 Women's & Men's Health: Contraception, Emergency Contraception, Menopause, BPH, ED & Overactive Bladder

16 Chapter 16: Immunization & Health Promotion

16.1 Immunization Practice: NACI Recommendations, Administration, Cold Chain & Adverse Events 16.2 Health Promotion: Smoking Cessation, Weight Management, Screening & Social Determinants of Health

17 Chapter 17: Patient Care Process, Communication & Stewardship

17.1 The Patient Care Process: Assessment, Care Planning & Patient Interviewing 17.2 Patient Education, Device Counselling, Health Literacy & Overcoming Barriers 17.3 Interprofessional Collaboration, Pharmacy Workflow, Team Delegation & Drug Shortage Stewardship

14.2 Osteoarthritis, Rheumatoid Arthritis & Gout

Key Takeaways Explain This Topic AI

Topical NSAIDs are first-line for knee and hand osteoarthritis, oral NSAIDs need GI and cardiovascular risk assessment, and opioids are generally avoided.

Methotrexate is the anchor DMARD in rheumatoid arthritis: once weekly with folic acid, regular blood monitoring, effective contraception, and no trimethoprim-sulfamethoxazole.

Before biologics or JAK inhibitors, screen for TB and hepatitis B and C and avoid live vaccines; JAK inhibitors carry Health Canada cardiovascular, cancer and thrombosis warnings.

Gout flares are treated early with an NSAID, low-dose colchicine or a corticosteroid, and allopurinol is continued during flares.

Allopurinol starts low (50 mg in CKD) and is titrated to a urate below 360 µmol/L with colchicine prophylaxis; colchicine with clarithromycin can be fatal.

Last updated: October 2026

Osteoarthritis, Rheumatoid Arthritis & Gout

Joint diseases are a frequent source of analgesic questions, immunosuppressant monitoring and serious drug interactions. The pharmacist's job differs for each: matching analgesic risk to comorbidities in osteoarthritis , safe disease-modifying therapy in rheumatoid arthritis , and a treat-to-target urate strategy in gout .

1. Osteoarthritis (OA)

Foundations for everyone: exercise and strengthening, weight loss if overweight (each kilogram lost reduces knee load), walking aids, and education.

Topical NSAIDs (diclofenac gel or solution) are first-line for knee and hand OA . Systemic exposure is only about 5 to 10% of oral dosing, which suits older adults and patients with GI or CV risk.

Oral NSAIDs: the most effective oral option, at the lowest dose for the shortest time.

Add a PPI if the patient is 65 or older, has a past ulcer, or takes anticoagulants, antiplatelets or corticosteroids.

Avoid in CKD, heart failure, uncontrolled hypertension, or after recent CV events. In PRECISION, moderate-dose celecoxib was cardiovascularly noninferior to naproxen and ibuprofen (section 13.1).

Acetaminophen gives only a small benefit in OA, but it remains reasonable when NSAIDs are unsafe, within the daily maximum.

Duloxetine helps chronic OA pain, especially with coexisting depression or widespread pain.

Intra-articular corticosteroid injections give short-term relief in flares.

Opioids are generally avoided for OA because of harms without durable benefit. Glucosamine and chondroitin lack convincing evidence.

2. Rheumatoid Arthritis (RA)

RA is a systemic autoimmune polyarthritis. Early disease-modifying therapy within the first months prevents erosions , and treatment aims at remission or low disease activity ("treat to target").

Conventional Synthetic DMARDs

Drug Key points Monitoring and counselling

Methotrexate (anchor drug) Once weekly (oral or SC), titrated to 20 to 25 mg/week. Give folic acid to reduce mouth sores, GI upset and liver test rises CBC, liver tests and creatinine at baseline and every 1 to 3 months. Limit alcohol. Teratogenic : effective contraception. Avoid TMP-SMX (additive antifolate marrow suppression). Daily-dosing errors can be fatal

Hydroxychloroquine Mild disease or combination therapy; dose 5 mg/kg/day or less of actual body weight Baseline eye exam, then annual retinal screening after 5 years (sooner with risk factors)

Sulfasalazine Combination therapy Orange urine and sweat (stains contact lenses); sulfonamide reactions; CBC and liver tests

Leflunomide Alternative to methotrexate Hepatotoxic and teratogenic with a very long half-life. Before pregnancy, a cholestyramine washout is needed

Biologic and Targeted Therapies

Options when methotrexate is inadequate: TNF inhibitors (adalimumab, etanercept, infliximab, certolizumab, golimumab), abatacept, tocilizumab, sarilumab and rituximab. Biosimilars exist for many, and provincial switching policies apply.

Before starting: screen for latent TB and hepatitis B and C , and update vaccinations. Live vaccines are avoided during therapy, and the drug is held during serious infections.

JAK inhibitors (tofacitinib, baricitinib, upadacitinib) are oral targeted agents. Health Canada warnings after the ORAL Surveillance trial: higher rates of serious cardiovascular events, cancer, thrombosis and death than with TNF inhibitors in patients 50 and older with a cardiovascular risk factor. Use them in older patients, smokers and those with CV or VTE risk only when no suitable alternative exists.

Glucocorticoids bridge until DMARDs work (6 to 12 weeks), at the lowest dose for the shortest time, with bone protection if they are prolonged.

  • 3. Gout
  • Acute Flare (Start Treatment as Early as Possible)

NSAID at full anti-inflammatory dose (for example, naproxen 500 mg twice daily), unless contraindicated.

Low-dose colchicine: 1.2 mg at onset, then 0.6 mg one hour later. It works best within 36 hours. High-dose regimens add toxicity without extra benefit.

Corticosteroids: oral prednisone (for example, 30 to 35 mg daily for 5 days) or an intra-articular injection. Useful in CKD or when NSAIDs and colchicine are unsafe.

Continue urate-lowering therapy (ULT) during a flare. Do not stop allopurinol.

Urate-Lowering Therapy

Indications: 2 or more flares a year, tophi, or radiographic damage. It is also considered after a first flare with CKD stage 3 or higher, very high urate, or kidney stones.

Allopurinol is first-line.

Start low: 100 mg daily or less, and 50 mg daily in moderate to severe CKD .

Titrate every 2 to 5 weeks to a serum urate below 360 µmol/L (below 300 µmol/L with tophi). The final dose can exceed renal-based "maximums" if titrated slowly and monitored.

HLA-B*5801 testing before starting is advised for patients of Han Chinese, Korean or Thai ancestry (and some guidelines add African ancestry). Carriers have a high risk of severe cutaneous reactions (SJS/TEN, DRESS).

Flare prophylaxis when starting ULT: colchicine 0.6 mg once or twice daily (or a low-dose NSAID) for 3 to 6 months, because rapid urate lowering mobilizes crystals.

Febuxostat is an alternative. It carries cardiovascular-death warnings, so it is avoided in established cardiovascular disease when alternatives exist.

Drugs that raise urate: thiazide and loop diuretics, low-dose ASA, cyclosporine and niacin. Losartan modestly lowers urate, which helps when a hypertensive patient needs an alternative to a thiazide.

Caution

Colchicine interactions: strong CYP3A4 or P-glycoprotein inhibitors (clarithromycin, ketoconazole and itraconazole, ritonavir, cyclosporine) can cause fatal colchicine toxicity (neuromyopathy, myelosuppression). Avoid the combination, or reduce the colchicine dose substantially. Moderate inhibitors such as diltiazem and verapamil also need dose reduction. Colchicine plus a statin increases myopathy risk.